Repetitive and restricted behaviour (Sensory Motor subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
1 finding from 1 review
Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Overall autism features (total score of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Social Relationships subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 23 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
Change in MMSE · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Cognitive function · people with Alzheimer's disease
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).
1 finding from 1 review